Parkinson's disease

Human Molecular Genetics

Volumn 16, Issue R2, 2007, Pages

  Thomas, Bobby ^a   Flint Beal, M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LRRK2 PROTEIN, HUMAN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PARKIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED PUTATIVE KINASE; PTEN-INDUCED PUTATIVE KINASE; SIGNAL PEPTIDE; SNCA PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

BIOLOGICAL MODEL; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; MUTATION; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; REVIEW;

ALPHA-SYNUCLEIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; MODELS, BIOLOGICAL; MUTATION; ONCOGENE PROTEINS; OXIDATION-REDUCTION; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 37349004102     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddm159     Document Type: Review

References (158)

1. Forno, L.S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 55, 259-272.
2. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24, 197-211.
3. Hardy, J., Cookson, M.R. and Singleton, A. (2003) Genes and parkinsonism. Lancet Neurol., 2, 221-228.
4. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
5. Yavich, L., Tanila, H., Vepsalainen, S. and Jakala, P. (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci., 24, 11165-11170.
6. Yavich, L., Jakala, P. and Tanila, H. (2006) Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J. Neurochem., 99, 724-732.
7. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
8. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
9. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
10. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) a-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
11. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA, 95, 6469-6473.
12. Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M.G. and Feany, M.B. (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci., 27, 3338-3346.
13. Tofaris, G.K., Garcia Reitbock, P., Humby, T., Lambourne, S.L., O'Connell, M., Ghetti, B., Gossage, H., Emson, P.C., Wilkinson, L.S., Goedert, M. et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci., 26, 3942-3950.
14. Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J.C., Marsh, L., Dawson, T.M., Jakala, P., Hartmann, T., Price, D.L. et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA, 102, 2162-2167.
15. Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello, R.J., Barbour, R., Huang, J., Kling, K., Lee, M. et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem., 281, 29739-29752.
16. Smith, W.W., Margolis, R.L., Li, X., Troncoso, J.C., Lee, M.K., Dawson, V.L., Dawson, T.M., Iwatsubo, T. and Ross, C.A. (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci., 25, 5544-5552.
17. Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C.H., Koyama, S., Nagasawa, H., Kimura, H., Kawanami, T. et al. (2006) The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci., 26, 9227-9238.
18. Ihara, M., Yamasaki, N., Hagiwara, A., Tanigaki, A., Kitano, A., Hikawa, R., Tomimoto, H., Noda, M., Takanashi, M., Mori, H. et al. (2007) Sept4, a component of presynaptic Scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron, 53, 519-533.
19. Shults, C.W., Barrett, J.M. and Fontaine, D. (2006) a-Synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy. Neurosci. Lett., 405, 223-225.
20. Bodner, R.A., Outeiro, T.F., Altmann, S., Maxwell, M.M., Cho, S.H., Hyman, B.T., McLean, P.J., Young, A.B., Housman, D.E. and Kazantsev, A.G. (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl Acad. Sci. USA, 103, 4246-4251.
21. Kramer, M.L. and Schulz-Schaeffer, W.J. (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci., 27, 1405-1410.
22. Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science, 313, 324-328.
23. Stichel, C.C., Zhu, X.R., Bader, V., Linnartz, B., Schmidt, S. and Lubbert, H. (2007) Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum. Mol. Genet., doi 10.1093/hmg/ddm083.
24. Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, N.A., Price, D.L. and Lee, M.K. (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci., 26, 41-50.
25. Klivenyi, P., Siwek, D., Gardian, G., Yang, L., Starkov, A., Cleren, C., Ferrante, R.J., Kowall, N.W., Abeliovich, A. and Beal, M.F. (2006) Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis., 21, 541-548.
26. Nieto, M., Gil-Bea, F.J., Dalfo, E., Cuadrado, M., Cabodevilla, F., Sanchez, B., Catena, S., Sesma, T., Ribe, E., Ferrer, I. et al. (2006) Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging, 27, 848-856.
27. Song, D.D., Shults, C.W., Sisk, A., Rockenstein, E. and Masliah, E. (2004) Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol., 186, 158-172.
28. Fan, Y., Limprasert, P., Murray, I.V., Smith, A.C., Lee, V.M., Trojanowski, J.Q., Sopher, B.L. and La Spada, A.R. (2006) Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum. Mol. Genet., 15, 3002-3011.
29. Tsigelny, I.F., Bar-On, P., Sharikov, Y., Crews, L., Hashimoto, M., Miller, M.A., Keller, S.H., Platoshyn, O., Yuan, J.X. and Masliah, E. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J., 274, 1862-1877.
30. Hashimoto, M., Bar-On, P., Ho, G., Takenouchi, T., Rockenstein, E., Crews, L. and Masliah, E. (2004) Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J. Biol. Chem., 279, 23622-23629.
31. Mosharov, E.V., Staal, R.G., Bove, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K.E., Moore, C.M., Troyer, M.D. et al. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci., 26, 9304-9311.
32. Hasegawa, T., Matsuzaki-Kobayashi, M., Takeda, A., Sugeno, N., Kikuchi, A., Furukawa, K., Perry, G., Smith, M.A. and Itoyama, Y. (2006) Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Lett., 580, 2147-2152.
33. Klegeris, A., Pelech, S., Giasson, B.I., Maguire, J., Zhang, H., McGeer, E.G. and McGeer, P.L. (2006) alpha-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2006.11.013.
34. Winner, B., Rockenstein, E., Lie, D.C., Aigner, R., Mante, M., Bogdahn, U., Couillard-Depres, S., Masliah, E. and Winkler, J. (2007) Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol. Aging, doi:10.1016/ j.neurobiolaging.2006.12.016.
35. Lee, H.J., Khoshaghideh, F., Lee, S. and Lee, S.J. (2006) Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci., 24, 3153-3162.
36. Sung, J.Y., Lee, H.J., Jeong, E.I., Oh, Y., Park, J., Kang, K.S. and Chung, K.C. (2007) alpha-Synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells. Neurosci. Lett., 416, 289-293.
37. Kontopoulos, E., Parvin, J.D. and Feany, M.B. (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet., 15, 3012-3023.
38. Zhang, Y., Gao, J., Chung, K.K., Huang, H., Dawson, V.L. and Dawson, T.M. (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA, 97, 13354-13359.
39. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 25, 302-305.
40. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
41. Dawson, T.M. (2006) Parkin and defective ubiquitination in Parkinson's disease. J. Neural Transm. Suppl., 70, 209-213.
42. Feany, M.B. and Pallanck, L.J. (2003) Parkin: a multipurpose neuroprotective agent? Neuron, 38, 13-16.
43. Henn, I.H., Bouman, L., Schlehe, J.S., Schlierf, A., Schramm, J.E., Wegener, E., Nakaso, K., Culmsee, C., Berninger, B., Krappmann, D. et al. (2007) Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci., 27, 1868-1878.
44. Fallon, L., Belanger, C.M., Corera, A.T., Kontogiannea, M., Regan-Klapisz, E., Moreau, F., Voortman, J., Haber, M., Rouleau, G., Thorarinsdottir, T. et al. (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol., 8, 834-842.
45. Riparbelli, M.G. and Callaini, G. (2007) The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis. Dev. Biol., 303, 108-120.
46. Kuroda, Y., Mitsui, T., Kunishige, M., Shono, M., Akaike, M., Azuma, H. and Matsumoto, T. (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet., 15, 883-895.
47. Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.W., Yang, L., Beal, M.F., Vogel, H. and Lu, B. (2006) Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl Acad. Sci. USA, 103, 10793-10798.
48. Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay, B.A. and Guo, M. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 441, 1162-1166.
49. Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.M. et al. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 441, 1157-1161.
50. Casarejos, M.J., Menendez, J., Solano, R.M., Rodriguez-Navarro, J.A., Garcia de Yebenes, J. and Mena, M.A. (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem., 97, 934-946.
51. LaVoie, M.J., Ostaszewski, B.L., Weihofen, A., Schlossmacher, M.G. and Selkoe, D.J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 11, 1214-1221.
52. Chung, K.K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J.C., Marsh, L., Dawson, V.L. and Dawson, T.M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 304, 1328-1331.
53. Smith, P.D., Crocker, S.J., Jackson-Lewis, V., Jordan-Sciutto, K.L., Hayley, S., Mount, M.P., O'Hare, M.J., Callaghan, S., Slack, R.S., Przedborski, S. et al. (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 100, 13650-13655.
54. Avraham, E., Rott, R., Liani, E., Szargel, R. and Engelender, S. (2007) Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J. Biol. Chem., 282, 12842-12850.
55. Wang, C., Ko, H.S., Thomas, B., Tsang, F., Chew, K.C., Tay, S.P., Ho, M.W., Lim, T.M., Soong, T.W., Pletnikova, O. et al. (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet., 14, 3885-3897.
56. Wong, E.S., Tan, J.M., Wang, C., Zhang, Z., Tay, S.P., Zaiden, N., Ko, H.S., Dawson, V.L., Dawson, T.M. and Lim, K.L. (2007) Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem., 282, 12310-12318.
57. Sang, T.K., Chang, H.Y., Lawless, G.M., Ratnaparkhi, A., Mee, L., Ackerson, L.C., Maidment, N.T., Krantz, D.E. and Jackson, G.R. (2007) A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J. Neurosci., 27, 981-992.
58. Moore, D.J., West, A.B., Dawson, V.L. and Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 57-87.
59. Thomas, B., von Coelln, R., Mandir, A.S., Trinkaus, D.B., Farah, M.H., Leong Lim, K., Calingasan, N.Y., Flint Beal, M., Dawson, V.L. and Dawson, T.M. (2007) MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol. Dis., 26, 312-322.
60. Perez, F.A., Curtis, W.R. and Palmiter, R.D. (2005) Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci., 6, 71.
61. von Coelln, R., Thomas, B., Andrabi, S.A., Lim, K.L., Savitt, J.M., Saffary, R., Stirling, W., Bruno, K., Hess, E.J., Lee, M.K. et al. (2006) Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J. Neurosci., 26, 3685-3696.
62. Solano, R.M., Menendez, J., Casarejos, M.J., Rodriguez-Navarro, J.A., Garcia de Yebenes, J. and Mena, M.A. (2006) Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity. Neuropharmacology, 51, 327-340.
63. Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C., Squitieri, F., Ibanez, P., Joosse, M. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256-259.
64. Hedrich, K., Djarmati, A., Schafer, N., Hering, R., Wellenbrock, C., Weiss, P.H., Hilker, R., Vieregge, P., Ozelius, L.J., Heutink, P. et al. (2004) DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology, 62, 389-394.
65. Bandopadhyay, R., Kingsbury, A.E., Cookson, M.R., Reid, A.R., Evans, I.M., Hope, A.D., Pittman, A.M., Lashley, T., Canet-Aviles, R., Miller, D.W. et al. (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain, 127, 420-430.
66. Zhang, L., Shimoji, M., Thomas, B., Moore, D.J., Yu, S.W., Marupudi, N.I., Torp, R., Torgner, I.A., Ottersen, O.P., Dawson, T.M. et al. (2005) Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet., 14, 2063-2073.
67. Canet-Aviles, R.M., Wilson, M.A., Miller, D.W., Ahmad, R., McLendon, C., Bandyopadhyay, S., Baptista, M.J., Ringe, D., Petsko, G.A. and Cookson, M.R. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA, 101, 9103-9108.
68. Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S.M., Takahashi, K. and Ariga, H. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep., 5, 213-218.
69. Paterna, J.C., Leng, A., Weber, E., Feldon, J. and Bueler, H. (2007) DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol. Ther., 15, 698-704.
70. Inden, M., Taira, T., Kitamura, Y., Yanagida, T., Tsuchiya, D., Takata, K., Yanagisawa, D., Nishimura, K., Taniguchi, T., Kiso, Y. et al. (2006) PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol. Dis., 24, 144-158.
71. Clements, C.M., McNally, R.S., Conti, B.J., Mak, T.W. and Ting, J.P. (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl Acad. Sci. USA, 103, 15091-15096.
72. Zhou, W. and Freed, C.R. (2005) DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J. Biol. Chem., 280, 43150-43158.
73. Shendelman, S., Jonason, A., Martinat, C., Leete, T. and Abeliovich, A. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol., 2, e362.
74. Zhou, W., Zhu, M., Wilson, M.A., Petsko, G.A. and Fink, A.L. (2006) The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol., 356, 1036-1048.
75. Moore, D.J., Zhang, L., Troncoso, J., Lee, M.K., Hattori, N., Mizuno, Y., Dawson, T.M. and Dawson, V.L. (2005) Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet., 14, 71-84.
76. Gorner, K., Holtorf, E., Waak, J., Pham, T.T., Vogt-Weisenhorn, D.M., Wurst, W., Haass, C. and Kahle, P.J. (2007) Structural determinants of the C-terminal helix-kink-helix motif essential for protein stability and survival promoting activity of DJ-1. J. Biol. Chem., 282, 13680-13691.
77. Hulleman, J.D., Mirzaei, H., Guigard, E., Taylor, K.L., Ray, S.S., Kay, C.M., Regnier, F.E. and Rochet, J.C. (2007) Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease. Biochemistry, 46, 5776-5789.
78. Ooe, H., Maita, C., Maita, H., Iguchi-Ariga, S.M. and Ariga, H. (2006) Specific cleavage of DJ-1 under an oxidative condition. Neurosci. Lett., 406, 165-168.
79. Choi, J., Sullards, M.C., Olzmann, J.A., Rees, H.D., Weintraub, S.T., Bostwick, D.E., Gearing, M., Levey, A.I., Chin, L.S. and Li, L. (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem., 281, 10816-10824.
80. Goldberg, M.S., Pisani, A., Haburcak, M., Vortherms, T.A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A. et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron, 45, 489-496.
81. Chen, L., Cagniard, B., Mathews, T., Jones, S., Koh, H.C., Ding, Y., Carvey, P.M., Ling, Z., Kang, U.J. and Zhuang, X. (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem., 280, 21418-21426.
82. Kim, R.H., Smith, P.D., Aleyasin, H., Hayley, S., Mount, M.P., Pownall, S., Wakeham, A., You-Ten, A.J., Kalia, S.K., Horne, P. et al. (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA, 102, 5215-5220.
83. Bretaud, S., Allen, C., Ingham, P.W. and Bandmann, O. (2007) p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem., 100, 1626-1635.
84. Pisani, A., Martella, G., Tscherter, A., Costa, C., Mercuri, N.B., Bernardi, G., Shen, J. and Calabresi, P. (2006) Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na {thorn} /K{thorn} ATPase. Neurobiol. Dis., 23, 54-60.
85. Yang, Y., Gehrke, S., Haque, M.E., Imai, Y., Kosek, J., Yang, L., Beal, M.F., Nishimura, I., Wakamatsu, K., Ito, S. et al. (2005) Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl Acad. Sci. USA, 102, 13670-13675.
86. Junn, E., Taniguchi, H., Jeong, B.S., Zhao, X., Ichijo, H. and Mouradian, M.M. (2005) Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc. Natl Acad. Sci. USA, 102, 9691-9696.
87. Zhong, N., Kim, C.Y., Rizzu, P., Geula, C., Porter, D.R., Pothos, E.N., Squitieri, F., Heutink, P. and Xu, J. (2006) DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J. Biol. Chem., 281, 20940-20948.
88. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
89. Klein, C., Grunewald, A. and Hedrich, K. (2006) Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology, 66, 1129-1130. author reply 1129-1130.
90. Gandhi, S., Muqit, M.M., Stanyer, L., Healy, D.G., Abou-Sleiman, P.M., Hargreaves, I., Heales, S., Ganguly, M., Parsons, L., Lees, A.J. et al. (2006) PINK1 protein in normal human brain and Parkinson's disease. Brain, 129, 1720-1731.
91. Leutenegger, A.L., Salih, M.A., Ibanez, P., Mukhtar, M.M., Lesage, S., Arabi, A., Lohmann, E., Durr, A., Ahmed, A.E. and Brice, A. (2006) Juvenile-onset Parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1. Arch. Neurol., 63, 1257-1261.
92. Beilina, A., Van Der Brug, M., Ahmad, R., Kesavapany, S., Miller, D.W., Petsko, G.A. and Cookson, M.R. (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl Acad. Sci. USA, 102, 5703-5708.
93. Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E.M. and Casari, G. (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet., 14, 3477-3492.
94. Sim, C.H., Lio, D.S., Mok, S.S., Masters, C.L., Hill, A.F., Culvenor, J.G. and Cheng, H.C. (2006) C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum. Mol. Genet., 15, 3251-3262.
95. Scheele, C., Petrovic, N., Faghihi, M.A., Lassmann, T., Fredriksson, K., Rooyackers, O., Wahlestedt, C., Good, L. and Timmons, J.A. (2007) The human PINK1 locus is regulated in vivo by a non-coding natural antisense RNA during modulation of mitochondrial function. BMC Genom., 8, 74.
96. Petit, A., Kawarai, T., Paitel, E., Sanjo, N., Maj, M., Scheid, M., Chen, F., Gu, Y., Hasegawa, H., Salehi-Rad, S. et al. (2005) Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem., 280, 34025-34032.
97. Deng, H., Jankovic, J., Guo, Y., Xie, W. and Le, W. (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys. Res. Commun., 337, 1133-1138.
98. Tang, B., Xiong, H., Sun, P., Zhang, Y., Wang, D., Hu, Z., Zhu, Z., Ma, H., Pan, Q., Xia, J.H. et al. (2006) Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum. Mol. Genet., 15, 1816-1825.
99. Muqit, M.M., Abou-Sleiman, P.M., Saurin, A.T., Harvey, K., Gandhi, S., Deas, E., Eaton, S., Payne Smith, M.D., Venner, K., Matilla, A. et al. (2006) Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem., 98, 156-169.
100. Murakami, T., Moriwaki, Y., Kawarabayashi, T., Nagai, M., Ohta, Y., Deguchi, K., Kurata, T., Takehisa, Y., Matsubara, E., Ikeda, M. et al. (2007) PINK1, a gene product of PARK6, accumulates in {alpha}-synucleinopathy brains. J. Neurol. Neurosurg. Psychiatry, 78, 653-654.
101. Hoepken, H.H., Gispert, S., Morales, B., Wingerter, O., Del Turco, D., Mulsch, A., Nussbaum, R.L., Muller, K., Drose, S., Brandt, U. et al. (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis., 25, 401-411.
102. Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W.S., Oldham, S., Xia, K., Wang, J., Bodmer, R. and Zhang, Z. (2006) Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl Acad. Sci. USA, 103, 13520-13525.
103. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
104. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
105. Hardy, J., Cai, H., Cookson, M.R., Gwinn-Hardy, K. and Singleton, A. (2006) Genetics of Parkinson's disease and parkinsonism. Ann. Neurol., 60, 389-398.
106. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.W., Savitt, J.M., Waldvogel, H.J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 60, 557-569.
107. Higashi, S., Moore, D.J., Colebrooke, R.E., Biskup, S., Dawson, V.L., Arai, H., Dawson, T.M. and Emson, P.C. (2007) Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem., 100, 368-381.
108. Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O. and Olson, L. (2006) LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol., 59, 714-719.
109. Taymans, J.M., Van den Haute, C. and Baekelandt, V. (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem., 98, 951-961.
110. Simon-Sanchez, J., Herranz-Perez, V., Olucha-Bordonau, F. and Perez-Tur, J. (2006) LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci., 23, 659-666.
111. Sakaguchi-Nakashima, A., Meir, J.Y., Jin, Y., Matsumoto, K. and Hisamoto, N. (2007) LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol., 17, 592-598.
112. Hatano, T., Kubo, S., Imai, S., Maeda, M., Ishikawa, K., Mizuno, Y. and Hattori, N. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet., 16, 678-690.
113. Zhu, X., Siedlak, S.L., Smith, M.A., Perry, G. and Chen, S.G. (2006) LRRK2 protein is a component of Lewy bodies. Ann. Neurol., 60, 617-618. author reply 618-619.
114. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587-593.
115. Li, C. and Beal, M.F. (2005) Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. Proc. Natl Acad. Sci. USA, 102, 16535-16536.
116. Deng, H., Le, W., Guo, Y., Hunter, C.B., Xie, W., Huang, M. and Jankovic, J. (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J. Neurol. Sci., 251, 102-106.
117. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA, 102, 16842-16847.
118. Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H. and Ueffing, M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet., 15, 223-232.
119. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 23, 329-341.
120. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
121. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 16, 223-232.
122. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 46, 1380-1388.
123. Greggio, E., Lewis, P.A., van der Brug, M.P., Ahmad, R., Kaganovich, A., Ding, J., Beilina, A., Baker, A.K. and Cookson, M.R. (2007) Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem., doi:10.1111/j.1471-4159.2007.04523.x.
124. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun., 357, 668-671.
125. Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA, 102, 18676-18681.
126. Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carri, M.T. and Barone, P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet., 16, 1319-1326.
127. White, L.R., Toft, M., Kvam, S.N., Farrer, M.J. and Aasly, J.O. (2007) MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J. Neurosci. Res., 85, 1288-1294.
128. Keeney, P.M., Xie, J., Capaldi, R.A. and Bennett, J.P., Jr (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci., 26, 5256-5264.
129. Beal, M.F. (2005) Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol., 58, 495-505.
130. Swerdlow, R.H., Parks, J.K., Miller, S.W., Tuttle, J.B., Trimmer, P.A., Sheehan, J.P., Bennett, J.P., Jr, Davis, R.E. and Parker, W.D., Jr (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol., 40, 663-671.
131. Gorell, J.M., Johnson, C.C., Rybicki, B.A., Peterson, E.L. and Richardson, R.J. (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology, 50, 1346-1350.
132. Langston, J.W., Ballard, P., Tetrud, J.W. and Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
133. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V. and Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 3, 1301-1306.
134. Thiruchelvam, M., Richfield, E.K., Baggs, R.B., Tank, A.W. and Cory-Slechta, D.A. (2000) The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci., 20, 9207-9214.
135. Lin, M.T. and Beal, M.F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787-795.
136. Bender, A., Krishnan, K.J., Morris, C.M., Taylor, G.A., Reeve, A.K., Perry, R.H., Jaros, E., Hersheson, J.S., Betts, J., Klopstock, T. et al. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet., 38, 515-517.
137. Kraytsberg, Y., Kudryavtseva, E., McKee, A.C., Geula, C., Kowall, N.W. and Khrapko, K. (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet., 38, 518-520.
138. Ekstrand, M.I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F.S., Trifunovic, A. et al. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA, 104, 1325-1330.
139. Liang, C.L., Wang, T.T., Luby-Phelps, K. and German, D.C. (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp. Neurol., 203, 370-380.
140. Dexter, D.T., Sian, J., Rose, S., Hindmarsh, J.G., Mann, V.M., Cooper, J.M., Wells, F.R., Daniel, S.E., Lees, A.J., Schapira, A.H. et al. (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol., 35, 38-44.
141. Chinta, S.J. and Andersen, J.K. (2006) Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic. Biol. Med., 41, 1442-1448.
142. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397-408.
143. McGill, J.K. and Beal, M.F. (2006) PGC-1alpha, a new therapeutic target in Huntington's disease? Cell, 127, 465-468.
144. Ramsey, C.P., Glass, C.A., Montgomery, M.B., Lindl, K.A., Ritson, G.P., Chia, L.A., Hamilton, R.L., Chu, C.T. and Jordan-Sciutto, K.L. (2007) Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol., 66, 75-85.
145. Lee, J.M. and Johnson, J.A. (2004) An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol., 37, 139-143.
146. Kobayashi, A., Kang, M.I., Watai, Y., Tong, K.I., Shibata, T., Uchida, K. and Yamamoto, M. (2006) Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol., 26, 221-229.
147. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D. and Yamamoto, M. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., 13, 76-86.
148. Dinkova-Kostova, A.T., Liby, K.T., Stephenson, K.K., Holtzclaw, W.D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G.W. et al. (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc. Natl Acad. Sci. USA, 102, 4584-4589.
149. Burton, N.C., Kensler, T.W. and Guilarte, T.R. (2006) In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology, 27, 1094-1100.
150. Shih, A.Y., Imbeault, S., Barakauskas, V., Erb, H., Jiang, L., Li, P. and Murphy, T.H. (2005) Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem., 280, 22925-22936.
151. Calkins, M.J., Jakel, R.J., Johnson, D.A., Chan, K., Kan, Y.W. and Johnson, J.A. (2005) Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc. Natl Acad. Sci. USA, 102, 244-249.
152. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., Mandir, A.S., Vila, M., McAuliffe, W.G., Dawson, V.L., Dawson, T.M. and Przedborski, S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 5, 1403-1409.
153. Teismann, P., Tieu, K., Choi, D.K., Wu, D.C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V. and Przedborski, S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA, 100, 5473-5478.
154. Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M.J., Kholodilov, N. and Burke, R.E. (2006) Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl Acad. Sci. USA, 103, 18757-18762.
155. Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., Harding, M., Bellen, H. and Mardon, G. (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development, 131, 2183-2194.
156. Palacino, J.J., Sagi, D., Goldberg, M.S., Krauss, S., Motz, C., Wacker, M., Klose, J. and Shen, J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem., 279, 18614-18622.
157. Darios, F., Corti, O., Lucking, C.B., Hampe, C., Muriel, M.P., Abbas, N., Gu, W.J., Hirsch, E.C., Rooney, T., Ruberg, M. et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet., 12, 517-526.
158. Meulener, M.C., Xu, K., Thomson, L., Ischiropoulos, H. and Bonini, N.M. (2006) Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc. Natl Acad. Sci. USA, 103, 12517-12522.